Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 11, 2001, Pages 1712-1719

  Takemoto, Masao ^a   Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Endothelium; Inflammation; Platelets; Vascular smooth muscle

Indexed keywords

CYCLIN DEPENDENT KINASE; CYTOKINE; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MEVALONIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN CDC42; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RAC PROTEIN; RAS PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RHO FACTOR; RHO KINASE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG EFFECT; HUMAN; INFLAMMATION; ISOPRENYLATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTE FUNCTION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0035572718     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq1101.098486     Document Type: Short Survey

References (121)

1. The future of best practice
2. Premature mortality from coronary heart disease: The Framingham study
3. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham study
4. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
5. Changes in risk factors and the decline in mortality from cardiovascular disease: The Framingham Heart Study
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group
8. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
9. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
10. Primary prevention of acute coronary events with lovastatin in men, women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study
11. The pathogenesis of atherosclerosis: A perspective for the 1990s
12. Serum cholesterol in young men and subsequent cardiovascular disease
13. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction?
14. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
15. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
16. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
17. Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease: Observations from the FATS Trial: Familial Atherosclerosis Treatment Study
18. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
19. Non-lipid-related effects of statins
20. Pleiotropic effects of statins in atherosclerosis and diabetes
21. Regulation of the mevalonate pathway
22. Rho GTPases and signaling networks
23. Rho GTPases and the actin cytoskeleton
24. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
25. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
26. Neuroprotection mediated by changes in the endothelial actin cytoskeleton
27. Small GTP-binding proteins and the regulation of the actin cytoskeleton
28. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
29. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta
30. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing tho GTPase-induced down- regulation of p27(Kip1)
31. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation
32. Stimulation of bone formation in vitro and in rodents by statins
33. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis
34. Molecular biology of atherosclerosis
35. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
36. S-Nitroso-glutathione inhibits platelet activation in vitro and in vivo
37. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
38. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia
39. Nitric oxide: An endogenous modulator of leukocyte adhesion
40. Cellular and molecular mechanisms of endothelial cell dysfunction
41. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: A novel mechanism underlying tolerance and cross-tolerance
42. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
43. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
44. Simvastatin, an HMG-coenzyme: A reductase inhibitor, improves endothelial function within 1 month
45. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
46. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
47. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits
48. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
49. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins
50. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
51. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress
52. Endothelial dysfunction in hypercholesterolemia: Mechanisms, pathophysiological importance, and therapeutic interventions
53. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species
54. Cell cycle progression: New therapeutic target for vascular proliferative disease
55. Effect of pravastatin on outcomes after cardiac transplantation
56. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins
57. Control of signal transduction and morphogenesis by Ras
58. Translational control of p27Kip1 accumulation during the cell cycle
59. Platelet activation in unstable coronary disease
60. Clinical-pathological correlations of coronary disease progression and regression
61. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
62. Specific platelet mediators and unstable coronary artery lesions: Experimental evidence and potential clinical implications
63. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol
64. Hypercholesterolemia and platelets
65. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
66. Platelet alpha 2-adrenergic receptors in hypercholesterolemia: Relationship between binding studies and epinephrine-induced platelet aggregation
67. 2+ and membrane dynamics in patients with primary hypercholesterolemia: Effects of pravastatin
68. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor
69. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys
70. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents
71. The evolving role of statins in the management of atherosclerosis
72. Influence of cholesterol-lowering on plasma membrane lipids and function
73. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin
74. Alternative binding assay of gp iib/iiia antagonists with a nonradioactive labeling method of platelets
75. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo, and in vitro
76. Elucidation of the role of plaque instability and rupture in acute coronary events
77. Pathogenesis of thrombosis in unstable angina
78. Atherosclerotic plaque rupture and thrombosis: Evolving concepts
79. Molecular bases of the acute coronary syndromes
80. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture
81. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture
82. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture
83. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization
84. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques
85. Acute coronary thrombosis: The role of plaque disruption and its initiation and prevention
86. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits
87. Effects of statins on vascular wall: Vasomotor function, inflammation, and plaque stability
88. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
89. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization
90. Atherosclerosis is an inflammatory disease
91. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line
92. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
93. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
94. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein e-deficient mice
95. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury
96. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: New concepts for cardiovascular disease
97. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: The role of mevalonic acid
98. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
99. The acute phase response
100. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort study, 1984 to 1992
101. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
102. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
103. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
104. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
105. C reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study
106. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia
107. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
108. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol and Recurrent Events (CARE) Investigators
109. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators
110. HMG-CoA reductase inhibitor therapy and stroke risk reduction: An analysis of clinical trials data
111. Multiple risk factor intervention trial: Risk factor changes and mortality results: Multiple Risk Factor Intervention Trial Research Group
112. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
113. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells
114. Statins as a newly recognized type of immunomodulator
115. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPase
116. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
117. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein
118. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
119. Hydroxymethylglutaryl coenzyme: A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae
120. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia
121. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis